Compare Live Nation Entertainment, Inc. (LYV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Medpace Holdings Inc — how do they compare? Live Nation Entertainment, Inc. trades at $172.16 (market cap $39.92B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Live Nation Entertainment, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Medpace Holdings Inc for 14 Days on average.
| LYV | MEDP | |
|---|---|---|
Market Cap | $39.92B | $16.82B |
Volume | 1,982,609 | 223,093 |
Sector | Media | Health |
52-Week High | $188.46 | $630.19 |
52-Week Low | $125.61 | $393.42 |
Typical Hold Time | 72 Days | 14 Days |
Enterprise Value | $42.13B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $170.33, down 0.3% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $25.20B in 2025, with net income of $496M, though margins remain thin at 1.96%. Recent news highlights strong fan demand and strategic partnerships, such as the Salesforce Agentforce expansion announced September 16, 2026. Analyst consensus is strongly bullish with a $208.18 price target, supported by 40 buy ratings.
The outlook for LYV is positive due to robust demand for live events and double-digit growth in deferred revenue, but risks include high valuation multiples, legal uncertainties from past DOJ scrutiny, and cost pressures. Earnings volatility is a concern after recent misses, though Q2 2026 beat expectations. Investors should weigh strong institutional support against execution risks in a competitive market.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
